DK2494047T3 - Multifunktionelle alleler - Google Patents
Multifunktionelle alleler Download PDFInfo
- Publication number
- DK2494047T3 DK2494047T3 DK10774391.6T DK10774391T DK2494047T3 DK 2494047 T3 DK2494047 T3 DK 2494047T3 DK 10774391 T DK10774391 T DK 10774391T DK 2494047 T3 DK2494047 T3 DK 2494047T3
- Authority
- DK
- Denmark
- Prior art keywords
- recombinase
- nsi
- coin
- orientation
- sites
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Claims (14)
1. Nukleinsyrekonstruktion, der omfatter: (a) målsøgende arme til at styre nukleinsyrekonstruktionen mod et målgen i en nukleinsyre i en celle; (b) en aktueringssekvens i sense-orientering i forhold til transkription af målgenet og en lægemiddelselektionskassette (DSC) i sense- eller antisense-orientering; (c) i antisense-orientering en nukleotidsekvens af interesse (NSI) og et COIN (konditionelt ved inversion-element); og (d) rekombinerbare enheder, hvor de rekombinerbare enheder omfatter to første par af sammenhørende rekombinasegenkendelsessteder, der genkendes af en første rekombinase, idet en første rekombinerbar enhed omfatter aktueringssekvensen, DSC og NSI, hvor den første rekombinerbare enhed flankeres af et par af de to første par af sammenhørende rekombinasegenkendelsessteder, der genkendes af den første rekombinase, en anden rekombinerbar enhed omfatter NSI, hvor den anden rekombinerbare enhed flankeres af et par af de to første par af sammenhørende rekombinasegenkendelsessteder, der genkendes af den første rekombinase, to “andet” par af sammenhørende rekombinasegenkendelsessteder, der genkendes af en anden rekombinase, og ét tredje par af sammenhørende rekombinasegenkendelsessteder, der genkendes af en tredje rekombinase; hvor de første par, de “andet” par og det tredje par af rekombinasegenkendelsessteder genkendes af forskellige rekombinaser; hvor de rekombinerbare enheder rekombinerer ved eksponering for en første rekombinase til frembringelse af en konditionel allel, der mangler aktueringssekvensen og DSC og indeholder NSI i sense-orientering og COIN i antisense-orientering; og hvor den konditionelle allel rekombinerer, når den yderligere eksponeres forden anden rekombinase, til frembringelse af en allel, der mangler NSI og har COIN i sense-orientering.
2. Fremgangsmåde til modificering afen ikke-human celle, der omfatter: målsøgning mod en nukleotidsekvens af interesse i en celle med en nukleinsyrekonstruktion ifølge krav 1 til frembringelse af en målcelle, eksponering af målcellen for den første rekombinase til frembringelse af den konditionelle allel og eksponering af den konditionelle allel for en anden rekombinase, der udskærer NSI og anbringer COIN i sense-orientering.
3. Fremgangsmåde ifølge krav 2, hvor NSI i cellen er et exon eller en nukleotidsekvens, der er forbundet med en fænotype.
4. Fremgangsmåde ifølge krav 3, hvor nukleotidsekvensen af interesse i cellen erstattes af nukleinsyrekonstruktionen ifølge krav 1.
5. Fremgangsmåde ifølge krav 4, hvor fænotypen bestemmes en første gang efter frembringelse af målcellen, men før eksponering for den første rekombinase.
6. Fremgangsmåde ifølge krav 5, hvor fænotypen bestemmes en anden gang efter eksponering for den første rekombinase.
7. Nukleinsyrekonstruktion, der omfatter: en lægemiddelselektionskassette (DSC), en reporter, et COIN, en nukleotidsekvens af interesse (NSI) og fem par af rekombinasesteder, der er anbragt blandt reporteren, DSC, COIN og NSI; hvor intet par af rekombinasesteder er identisk med noget andet par, og hvor et første to par af rekombinasesteder genkendes af den samme første rekombinase, et “andet” to par af rekombinasesteder genkendes af den samme anden rekombinase, og et femte par af rekombinasesteder genkendes af en tredje rekombinase; hvor den første, anden og tredje rekombinase ikke er den samme, og hvor i forhold til transkriptionsretningen reporteren er i sense-orientering, NSI er i antisense-orientering, COIN er i antisense-orientering, og DSC er i sense- eller antisense-orientering; hvor rekombinasestederne er anbragt i rekombinerbare enheder, der omfatter (i) en første rekombinerbar enhed, der omfatter aktueringssekvensen, DSC og NSI, hvor den første rekombinerbare enhed flankeres af et par af de to første par af sammenhørende rekombinasegenkendelsessteder, der genkendes af den første rekombinase; og (ii) en anden rekombinerbar enhed, der omfatter NSI, hvor den anden rekombinerbare enhed flankeres af et par af de to første par af sammenhørende rekombinasegenkendelsessteder, der genkendes af den første rekombinase; og hvor de første to par og de “andet” to par af rekombinasesteder er anbragt, således at der ved eksponering for den første rekombinase dannes en modificeret allel, hvor de første to par af rekombinasesteder styrer udskæring af reporteren, udskæring af DSC og inversion af NSI til sense-orientering, og COIN opretholdes i antisense-orientering, og enten (a) de “andet” to par af rekombinasesteder er anbragt, således at der ved eksponering for den anden rekombinase sker det, at NSI udskæres, og COIN anbringes i sense-orientering; eller (b) de “andet” to par af rekombinasesteder er anbragt, således at der ved eksponering for den anden rekombinase sker det, at NSI anbringes i antisense-orientering, og COIN anbringes i sense-orientering.
8. Nukleinsyrekonstruktion ifølge krav 7, hvor det femte par af rekombinasesteder er anbragt, således at der ved eksponering for den tredje rekombinase og i fravær af eksponering for den første eller den anden rekombinase sker det, at den femte rekombinase udskærer COIN, NSI og DSC, og opretholder reporteren i sense-orientering.
9. Nukleinsyrekonstruktion ifølge krav 7, hvor nukleinsyrekonstruktionen er indsat i et gen, og konstruktionen i forhold til transkriptionsretningen af genet fra 5’ mod 3’ omfatter en reporter i sense-orientering, en DSC i sense- eller antisense-orientering, en NSI i antisense-orientering og et COIN i antisense-orientering.
10. Nukleinsyrekonstruktion ifølge krav 9, hvor DSC er i sense-orientering.
11. Nukleinsyrekonstruktion ifølge krav 7, hvor nukleinsyrekonstruktionen er indsat i et gen, og konstruktionen i forhold til transkriptionsretningen af genet fra 5’ mod 3’ omfatter et COIN i antisense-orientering, en NSI i antisense-orientering, en DSC i sense- eller antisense-orientering og en reporter i sense-orientering.
12. Nukleinsyrekonstruktion ifølge krav 11, hvor DSC er i sense-orientering.
13. Nukleinsyrekonstruktion ifølge krav 7, hvor nukleinsyrekonstruktionen er indsat i et gen, og konstruktionen i forhold til transkriptionsretningen af genet fra 5’ mod 3’ omfatter en NSI i antisense-orientering, en DSC i sense- eller antisense-orientering, en reporter i sense-orientering og et COIN i antisense-orientering.
14. Nukleinsyrekonstruktion ifølge krav 13, hvor DSC er i sense-orientering.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25607809P | 2009-10-29 | 2009-10-29 | |
PCT/US2010/054654 WO2011059799A1 (en) | 2009-10-29 | 2010-10-29 | Multifunctional alleles |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2494047T3 true DK2494047T3 (da) | 2017-04-10 |
Family
ID=43244777
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10774391.6T DK2494047T3 (da) | 2009-10-29 | 2010-10-29 | Multifunktionelle alleler |
DK16196614.8T DK3147362T3 (da) | 2009-10-29 | 2010-10-29 | Multifunktionelle alleler |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16196614.8T DK3147362T3 (da) | 2009-10-29 | 2010-10-29 | Multifunktionelle alleler |
Country Status (13)
Country | Link |
---|---|
US (4) | US20110104799A1 (da) |
EP (2) | EP3147362B1 (da) |
JP (3) | JP5908405B2 (da) |
CN (2) | CN106191126B (da) |
AU (1) | AU2010319894B2 (da) |
CA (1) | CA2779858C (da) |
CY (2) | CY1118659T1 (da) |
DK (2) | DK2494047T3 (da) |
ES (2) | ES2613662T3 (da) |
PL (2) | PL2494047T3 (da) |
PT (2) | PT3147362T (da) |
TR (1) | TR201903376T4 (da) |
WO (1) | WO2011059799A1 (da) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2779858C (en) | 2009-10-29 | 2019-10-29 | Aris N. Economides | Multifunctional alleles |
SG10201702445TA (en) | 2012-04-25 | 2017-04-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
US9510569B2 (en) * | 2013-03-13 | 2016-12-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation |
BR112015026197B1 (pt) | 2013-04-16 | 2022-12-06 | Regeneron Pharmaceuticals, Inc | Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente |
CA2917714A1 (en) | 2013-08-07 | 2015-02-12 | Regeneron Pharmaceuticals, Inc. | Lincrna-deficient non-human animals |
EP3080279B1 (en) | 2013-12-11 | 2018-09-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
ES2784754T3 (es) | 2014-06-06 | 2020-09-30 | Regeneron Pharma | Métodos y composiciones para modificar un locus objetivo |
PL3155099T3 (pl) | 2014-06-23 | 2018-08-31 | Regeneron Pharmaceuticals, Inc. | Łączenie dna mediowane nukleazą |
DK3161128T3 (da) | 2014-06-26 | 2018-11-05 | Regeneron Pharma | Fremgangsmåder og sammensætninger til målrettede gentiske modifikationer og fremgangsmåder til anvendelse heraf |
ES2741387T3 (es) | 2014-10-15 | 2020-02-10 | Regeneron Pharma | Métodos y composiciones para generar o mantener células pluripotentes |
LT3221457T (lt) | 2014-11-21 | 2019-06-10 | Regeneron Pharmaceuticals, Inc. | Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas |
NZ732895A (en) | 2014-12-19 | 2022-05-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification through single-step multiple targeting |
IL274285B (en) | 2015-03-16 | 2022-07-01 | Regeneron Pharma | Non-human animals exhibiting reduced upper and lower motor neuron function and sensory perception |
CN108884475A (zh) * | 2016-04-11 | 2018-11-23 | 应用干细胞有限公司 | 转基因的位点特异性整合 |
KR20240016444A (ko) | 2016-05-20 | 2024-02-06 | 리제너론 파마슈티칼스 인코포레이티드 | 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법 |
US10548302B2 (en) | 2016-07-29 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy |
CN107779462B (zh) * | 2016-08-29 | 2021-06-04 | 中国科学院分子细胞科学卓越创新中心 | 双同源重组谱系示踪技术 |
WO2018096356A1 (en) * | 2016-11-28 | 2018-05-31 | Horizon Discovery Limited | Methods for conditional gene knock-out |
SG11201906735RA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
WO2019006034A1 (en) | 2017-06-27 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS |
CN111163633B (zh) | 2017-09-29 | 2022-09-09 | 瑞泽恩制药公司 | 包含人源化ttr基因座的非人类动物及其使用方法 |
CA3076371C (en) | 2017-11-10 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising slc30a8 mutation and methods of use |
AU2018375796A1 (en) | 2017-11-30 | 2020-04-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TRKB locus |
JP2021526815A (ja) | 2018-06-13 | 2021-10-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 進行性骨化性線維異形成症のげっ歯類モデル |
SG11202105189RA (en) | 2018-12-20 | 2021-06-29 | Regeneron Pharma | Nuclease-mediated repeat expansion |
JP2022527809A (ja) | 2019-04-03 | 2022-06-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物 |
SG11202108454RA (en) | 2019-04-04 | 2021-09-29 | Regeneron Pharma | Non-human animals comprising a humanized coagulation factor 12 locus |
EP3801011A1 (en) | 2019-06-04 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
BR112021025425A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre |
WO2021092513A1 (en) | 2019-11-08 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | Crispr and aav strategies for x-linked juvenile retinoschisis therapy |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
EP4096396A1 (en) | 2020-01-28 | 2022-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
WO2021158883A1 (en) | 2020-02-07 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized klkb1 locus and methods of use |
EP4125348A1 (en) | 2020-03-23 | 2023-02-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
WO2021263146A2 (en) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
EP4259279A1 (en) | 2020-12-14 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
US20230293727A1 (en) | 2021-10-26 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy |
WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2023220697A1 (en) * | 2022-05-12 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Inducible recombinase systems |
WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
JP2024021835A (ja) * | 2022-08-04 | 2024-02-16 | 株式会社豊田中央研究所 | 相同組換え方法 |
WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1092768A1 (en) * | 1999-10-16 | 2001-04-18 | ARTEMIS Pharmaceuticals GmbH | Conditional gene trapping construct for the disruption of genes |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
US7074611B2 (en) * | 2001-04-27 | 2006-07-11 | Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) | Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof |
US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
US7205148B2 (en) * | 2003-06-11 | 2007-04-17 | Regeneron Pharmaceuticals, Inc. | Genome mutation by intron insertion into an embryonic stem cell genome |
US7582741B2 (en) * | 2004-07-26 | 2009-09-01 | University Of Massachusetts | Conditional disruption of dicer1 in cell lines and non-human mammals |
DK1815001T3 (da) * | 2004-11-26 | 2011-05-16 | Helmholtz Zentrum Muenchen | Genfældekassetter til tilfældig og målrettet konditioneret geninaktivering |
EP1662005A1 (en) * | 2004-11-26 | 2006-05-31 | FrankGen Biotechnologie AG | Enhancer-containing gene trap vectors for random and targeted gene trapping |
CA2779858C (en) | 2009-10-29 | 2019-10-29 | Aris N. Economides | Multifunctional alleles |
-
2010
- 2010-10-29 CA CA2779858A patent/CA2779858C/en active Active
- 2010-10-29 ES ES10774391.6T patent/ES2613662T3/es active Active
- 2010-10-29 AU AU2010319894A patent/AU2010319894B2/en active Active
- 2010-10-29 DK DK10774391.6T patent/DK2494047T3/da active
- 2010-10-29 CN CN201610565668.XA patent/CN106191126B/zh active Active
- 2010-10-29 CN CN201080056458.9A patent/CN102666854B/zh active Active
- 2010-10-29 PL PL10774391T patent/PL2494047T3/pl unknown
- 2010-10-29 EP EP16196614.8A patent/EP3147362B1/en active Active
- 2010-10-29 JP JP2012537099A patent/JP5908405B2/ja active Active
- 2010-10-29 PT PT16196614T patent/PT3147362T/pt unknown
- 2010-10-29 EP EP10774391.6A patent/EP2494047B1/en active Active
- 2010-10-29 US US12/915,447 patent/US20110104799A1/en not_active Abandoned
- 2010-10-29 PT PT107743916T patent/PT2494047T/pt unknown
- 2010-10-29 ES ES16196614T patent/ES2716981T3/es active Active
- 2010-10-29 PL PL16196614T patent/PL3147362T3/pl unknown
- 2010-10-29 WO PCT/US2010/054654 patent/WO2011059799A1/en active Application Filing
- 2010-10-29 DK DK16196614.8T patent/DK3147362T3/da active
- 2010-10-29 TR TR2019/03376T patent/TR201903376T4/tr unknown
-
2013
- 2013-07-12 US US13/940,609 patent/US10392633B2/en active Active
-
2016
- 2016-02-01 JP JP2016017198A patent/JP6085696B2/ja active Active
- 2016-07-28 JP JP2016148272A patent/JP6333316B2/ja active Active
-
2017
- 2017-01-26 CY CY20171100118T patent/CY1118659T1/el unknown
-
2019
- 2019-03-26 CY CY20191100345T patent/CY1121457T1/el unknown
- 2019-07-01 US US16/459,236 patent/US11319557B2/en active Active
-
2022
- 2022-04-01 US US17/712,003 patent/US20220220510A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11319557B2 (en) | Multifunctional alleles | |
US20210037799A1 (en) | Transgenic animals and methods of use | |
Prosser et al. | Mosaic complementation demonstrates a regulatory role for myosin VIIa in actin dynamics of stereocilia | |
JP2003512053A (ja) | 遺伝子破壊用条件付遺伝子トラッピング構築物 | |
US7473557B2 (en) | Method for targeting transcriptionally active loci | |
JP4359498B2 (ja) | 転写活性な座を標的化する方法 | |
US7625755B2 (en) | Conditional knockout method for gene trapping and gene targeting using an inducible gene silencer | |
AU2015203003B2 (en) | Multifunctional alleles | |
Wefers et al. | Design and generation of gene‐targeting vectors |